Compare LXRX & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LXRX | LBRX |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.4M | 602.6M |
| IPO Year | 2000 | N/A |
| Metric | LXRX | LBRX |
|---|---|---|
| Price | $1.64 | $24.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $3.23 | ★ $49.00 |
| AVG Volume (30 Days) | ★ 2.3M | 185.8K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,081,000.00 | N/A |
| Revenue This Year | $56.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2481.48 | N/A |
| 52 Week Low | $0.32 | $13.40 |
| 52 Week High | $1.83 | $25.60 |
| Indicator | LXRX | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 56.98 |
| Support Level | $1.07 | $22.48 |
| Resistance Level | $1.65 | $24.70 |
| Average True Range (ATR) | 0.10 | 1.29 |
| MACD | 0.02 | -0.11 |
| Stochastic Oscillator | 93.42 | 65.59 |
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.